Just as developing safe therapies is a focus of KindredBio, the quality of those pharmaceuticals is also important. The FDA regulates the quality of the pharmaceuticals using a standard called Current Good Manufacturing Practices (cGMP) for human pharmaceuticals. KindredBio believes our horses’ therapies should be made with the same high standards we use for human pharmaceuticals. We develop and manufacture our products in a cGMP environment. To that end, KindredBio is commissioning its own dedicated cGMP biologics manufacturing facility, in close proximity to the development labs in Burlingame, CA. The facility will implement state of the art Single Use Technology and will have the capacity to meet the requirements for the clinical and commercial KindredBio Biologics supply.
At KindredBio, development and manufacturing teams work in synergy. Our manufacturing facility allows a seamless transfer of the molecules from the development to manufacturing stage, tight control over the steps and processes, and provides a unique setting for the development and manufacturing of high quality species-specific veterinary biologics.